1 / 4

PICO

PICO. P: 60 year old male with idiopathic pulmonary fibrosis I: addition of oral acetylcysteine to standard therapy C: standard therapy O: Mortality, 6 min walk test, dyspnea, exercise capacity, quality of life, safety and pulmonary function tests. Search Strategy.

tea
Download Presentation

PICO

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PICO • P: 60 year old male with idiopathic pulmonary fibrosis • I: addition of oral acetylcysteine to standard therapy • C: standard therapy • O: Mortality, 6 min walk test, dyspnea, exercise capacity, quality of life, safety and pulmonary function tests

  2. Search Strategy • Search/MeSH terms: “acetylcysteine”, “N-acetylcysteine”, “idiopathic pulmonary fibrosis” • Limits: english, humans • Databases: ACP Journal Club, ACP Pier, Bandolier, Clinical Evidence, PubMed, Cochrane Library, Embase, IPA, Web of Science • One RCT found

  3. Results N Engl J Med 2005 353; 2229-2242

  4. Conclusion • Although there is a statistically significant improvement in PFTs, this did not correlate to an improvement in mortality and dyspnea scores. • Mortality and adverse event rates were not statistically significant. • There is insufficient evidence to recommend the addition of acetylcysteine 600 mg PO TID to standard therapy for the treatment of idiopathic pulmonary fibrosis.

More Related